Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer headquartered in Mechelen, Belgium. The report covers the month of November 2017, specifically referencing a press release issued on November 2, 2017, which is attached as Exhibit 99.1. The filing incorporates this press release by reference into the Company's Registration Statements on Forms F-3 and S-8.
Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing serves solely to disseminate the attached press release and does not include a financial statement or performance summary.
Material Changes
The filing text does not provide details regarding material changes versus prior periods. The content is limited to the administrative submission of a press release dated November 2, 2017. Specific operational or financial changes described in the press release are not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or contingencies. These details would be contained within the attached Exhibit 99.1 (Press Release), the content of which is not provided in the input text.
Key Facts for Investor Verification
- Company Identity: The registrant is Galapagos NV, not Lakefront Biotherapeutics NV (as noted in the request metadata).
- Document Purpose: This filing is a procedural vehicle to incorporate a press release dated November 2, 2017, into SEC registration statements.
- Data Availability: No financial metrics or specific business updates are present in the filing text itself; investors must review the attached Exhibit 99.1 for substantive information.
- Regulatory Status: The company files annual reports under Form 20-F.